The investigational varicella vaccine (hereafter referred to as VNS vaccine) is a new
candidate varicella vaccine derived from the Oka strain. The main rationale for the
development of VNS vaccine is to provide an additional alternative varicella vaccine as an advantage from a public health perspective to prevent varicella disease

A germ (bacterium) called meningococcus, or Neisseria meningitidis, can cause several serious diseases, including meningitis and blood infection. Meningitis affects the brain and spinal cord. It can cause hearing loss, seizures, learning and behavior problems, severe brain damage and even death. Meningitis can happen to anyone but is more common in teenagers and young children, including babies. This research study will help us learn about vaccines that protect against diseases caused by different types of meningococcus germs: types A, B, C, W, Y.

This study is being conducted to learn more about the safety and immune response of the study vaccine MenABCWY when 2 doses are given 24 months apart (0,24-month schedule) or 48 months apart (0,48-month schedule). The study will be conducted in healthy adolescents from 11 to 14 years of age.

INVESTED is a multi-site trial comparing high-dose (60 μg per vaccine viral strain) trivalent influenza vaccine to standard-dose (15 μg per viral strain) quadrivalent influenza vaccination for up to three influenza seasons in high-risk cardiovascular disease patients with a history of myocardial infarction in the previous 12 months OR history of heart failure hospitalization in the previous 24 months. Subjects will be randomly assigned to receive either the high-dose or standard-dose vaccine.